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Finasteride has been used for the treatment of benign prostate hyperplasia (BPH) for years, but some side
effects, including male breast cancer (MBC), have been reported. We report a case of breast cancer in a
male patient who received ﬁnasteride therapy for BPH, and to our knowledge, our report is believed to be
the ﬁrst in Taiwan. The patient was a 59-year-old man who received ﬁnasteride therapy for BPH for
4 years. He found a palpable mass in his left breast 2 months prior to diagnosis. Ultrasound-guided core
biopsy showed invasive ductal carcinoma. A simple mastectomy was performed followed by chemo-
therapy with tamoxifen.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.1. Introduction
Finasteride is a type II 5a-reductase inhibitor that blocks the
conversion of testosterone to dihydrotestosterone. Finasteride is used
for the treatment of benign prostate hyperplasia (BPH) and andro-
genetic alopecia. Male breast cancer is a rare side effect of ﬁnasteride.
Here, we reported the case of a 59-year-old man with breast cancer
during ﬁnasteride therapy, and a review of the literature.
2. Case report
A 59-year-old man visited our department for microscopic he-
maturia during physical checkup in 2005. In addition, he com-
plained of dribbling and incomplete emptying when voiding for a
long time. He did not have a medical history of other diseases
including diabetes mellitus and hypertension. He also had no
family history of cancer or hereditary disease. Digital examination
revealed moderate enlargement of the prostate with a smooth
surface. Ultrasound examination showed that the volume of pros-
tate was 28.1 cm3. The prostate speciﬁc antigen (PSA) level was
within normal limits. The patient was administered tamsulosin
0.2 mg once daily (QD). He was regularly followed-up at our
department. We initiated administration of ﬁnasteride 5 mg QD in
March 2006; then the dose of ﬁnasteride was reduced to 2.5 mg QDment of Surgery, Chang Gung
uan 333, Taiwan.
ciation. Published by Elsevier Taiwbecause of decreased libido in March 2007. The condition improved
after reducing the dose of ﬁnasteride. We had followed the prostate
volume (every 6 months in the ﬁrst year) which was 21.3 mL and
21.1 mL in March 2007 and October 2007, respectively. The PSA
level (examined every 3 months) did not show an obvious increase
between 2007 and 2010. However, he found a palpable mass over
his left breast and went to our general surgical department in
March 2011. Physical examination showed a 1 cm movable nodule
in the left upper outer quadrant of the breast in 2 o’clock position
and 0.5 cm from the nipple. Neither discharge nor nipple retraction
was noted. Breast sonography revealed a well-deﬁned tumor
measuring 1.3 cm in the retroareolar area of the left upper outer
breast (Fig. 1). Ultrasound-guided core biopsy showed invasive
ductal carcinoma. Simple mastectomy of the left breast was per-
formed smoothly. Grossly, a 1.4 cm white, ﬁrm with lobulated
tumor was noted (Fig. 2). Histopathologic ﬁnding was inﬁltrative
nests and neoplastic glands of intermediate grade ductal carcinoma
with microcalciﬁcation (Fig. 3). Finally, the condition of the patient
was diagnosed as left breast intraductal carcinoma, T1cN0M0,
Grade I, estrogen receptor: 3þ, progesterone receptor: 3þ, Her2:
2þ. Administration of ﬁnasteride was discontinued. The patient
was administered adjuvant chemotherapy with tamoxifen.3. Discussion
The incidence of breast cancer is lower in men than women at
about 1.0/100,000maneyears.1 Themedian age of men at diagnosisan LLC. Open access under CC BY-NC-ND license.
Fig. 3. (A) Tumor cell inﬁltration with neoplastic gland of left breast (hematoxylin and
eosin stain, 40). (B) Tumor cells inﬁltrating as solid nests with moderate nuclear
pleomorphism of left breast (hematoxylin and eosin stain, 200).
Fig. 1. Breast sonography reveals a 1.3 cmwell deﬁned tumor in left upper outer breast
retroareolarly.
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with breast cancer have a lower survival rate than women because
of older age at diagnosis, more advanced stage at diagnosis of
disease, and lack of awareness.3
The risk factors for MBC include diabetes mellitus, orchitis/
epididymitis, Klinefelter’s syndrome, and gynecomastia. Painless
subareloar mass is the most common symptom. In addition, other
symptoms such as discharge or bleeding, and nipple retractionmay
occur. Similar to female breast cancer, MBC is treated with surgical
management, radiation, and chemotherapy.4 Most men with MBC
are treated with either simple, radical, or modiﬁed radical mas-
tectomy.5 There is no strong evidence to support postmastectomy
radiation therapy of MBC.6 Adjuvant chemotherapy with tamoxifen
showed a signiﬁcant improvement in 5-year survival (61% vs. 44%).7
The status of relative estrogen excess or androgen deﬁcit increases
the risk of breast cancer in both women and men.8 Finasteride
inhibits type II 5a-reductase, which converts testosterone to dihy-
drotestosterone. Finasteride shrinks androgen-dependent prostate
tissue by the above mechanism. This process may alter estrogen/
androgen ratio and may increase the risk of breast cancer or
gynecomastia. A total of 50 BPH patients with MBC have been re-
ported worldwide.9 A strong correlation between ﬁnasteride and
MBC is based on a study by the Medical Therapy of Prostatic
Symptoms.10 This study included 3047 men consuming 5 mg
ﬁnasteride, 8 mg doxazosin, of a combination of 5 mg ﬁnasteride
and 8 mg doxazosin, and placebo. Of these 3047 men, four had
breast cancer (3 in the ﬁnasteride group and 1 in the combination
group). The incidence (4/3047) was higher than that in the general
population (1.0/100,000 maneyears). BPH patients with ﬁnasterideFig. 2. Grossly, a 1.4 cm 1.1 cm 0.6 cmwhite, ﬁrm, and lobulated tumor of left breast.therapy should be educated for self-examination of breasts. In
addition, physicians should perform further studies in such
patients who have symptoms of breast cancers.
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